The U.S. Food and Drug Administration has approved Tascenso ODT, a bioequivalent formulation of the multiple sclerosis (MS) therapy Gilenya (fingolimod), at a higher patient dose, according to the pharmaceutical company that will market the treatment in the U.S.

The newly approved therapy, which is delivered as disintegrating tablets, is expected to be available to patients in February, Cycle Pharmaceuticals said in a company press release.

A bioequivalent medicine is one that has the same active ingredient and is proven to be equally safe and effective as an original medication. This novel formulation of fingolimod was developed by Handa Neuroscience, which partnered with Cycle to commercialize the therapy in the U.S.

The new medication is approved for the same indications as the original formulation — specifically, for children and adults, ages 10 and older. It is indicated for patients with clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS).

Like Gilenya, the bioequivalent formulation is available in two dose strengths: 0.25 mg and 0.5 mg. However, while the original is available in regular capsules that must be swallowed, Tascenso ODT is delivered as orally disintegrating tablets (ODT) that dissolve on the tongue in just a few seconds.

The commercial launch of the bioequivalent formulation will be accompanied by a full patient support program, according to Cycle. That program aims to address a care gap and financial difficulties patients may face when the patient support program for Gilenya is withdrawn on March 31.

The Gilenya GO program was designed to offer patients ongoing one-on-one support, including navigation of insurance coverage and educational resources, when starting on the therapy. Among the offerings is financial assistance for patients, including a $0 copay program to help keep the medication affordable.

However, generic versions of Gilenya are expected to become available during this year — and this type of assistance will no longer be offered by the company. Novartis will continue to offer co-pay support for patients on Gilenya only until the end of 2023.

Cycle’s program, called Cycle Vita, will offer similar support to the GO program. The company believes Tascenso ODT and CycleVita are an option for patients who may need to switch from Gilenya in light of Gilenya GO’s cessation, but also for patients starting on fingolimod treatment for the first time.

Tascenso ODT was first approved in December 2021 at a 0.25 mg dose for pediatric patients, 10 and older, who weighed up to 40 kg (almost 90 pounds).

Now, the FDA approved the higher, 0.5 mg dose for adult and pediatric patients weighing 40 kg or more, making the medication available for the exact same indications as Gilenya.

To support that approval, studies were conducted that established Tascenso ODT’s bioequivalence to Gilenya. Bioequivalence means it has the same safety profile, side effects, and effectiveness.

For patients stopping Gilenya this year, Tascenso could be a promising alternative to help avoid disease progression once Gilenya is stopped.

“I’m incredibly pleased that eligible persons with MS will be able to continue to be treated with fingolimod, via Tascenco ODT, where appropriate, meaning that their ongoing therapy remains consistent,” said Jon Santoro, MD, an associate professor of neurology and pediatrics at the University of Southern California and director of neuroimmunology at the Children’s Hospital of Los Angeles.

“This will reduce therapeutic uncertainty given the potentially challenging circumstances they could have faced had an alternative bioequivalent not been made available,” Santoro added.

SOURCE